Cargando…
Panic Disorder and Chronic Caffeine Use: A Case-control Study
BACKGROUND: Acute administration of caffeine produces panic attacks in most Panic Disorder (PD) patients, but little is known about chronic caffeine use in these patients. OBJECTIVE: To assess caffeine use in patients with PD and to ascertain if caffeine consumption is associated with sociodemograph...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882139/ https://www.ncbi.nlm.nih.gov/pubmed/31819760 http://dx.doi.org/10.2174/1745017901915010120 |
_version_ | 1783474089492480000 |
---|---|
author | Santos, Veruska Andrea Hoirisch-Clapauch, Silvia Nardi, Antonio E. Freire, Rafael Christophe |
author_facet | Santos, Veruska Andrea Hoirisch-Clapauch, Silvia Nardi, Antonio E. Freire, Rafael Christophe |
author_sort | Santos, Veruska Andrea |
collection | PubMed |
description | BACKGROUND: Acute administration of caffeine produces panic attacks in most Panic Disorder (PD) patients, but little is known about chronic caffeine use in these patients. OBJECTIVE: To assess caffeine use in patients with PD and to ascertain if caffeine consumption is associated with sociodemographic or clinical features. METHODS: 65 adults with PD and 66 healthy controls were included in the current study. Their caffeine intake within the previous week was quantified with a questionnaire and compared. Harmful caffeine use was defined as consumption above 400 mg/day of caffeine. We tested for correlations between caffeine intake, demographic and clinical features. RESULTS: Patients consumed significantly more caffeine than controls (P < 0.001). 14% (N = 9) of the PD patients made harmful use of caffeine. The use of caffeine-containing medications was observed in 40% (N = 26) of the PD patients and 6% (N = 4) of controls. Consumption of energy drinks was observed in 11% (N = 7) of PD patients and in none of the healthy subjects. Patients reported sleeping significantly less than controls (P < 0.001). In PD patients, caffeine consumption was not correlated with the presence of panic attacks or comorbidity with depression. The use of benzodiazepines or sedative medications was not correlated with caffeine intake. CONCLUSION: High caffeine consumption in PD patients could be explained by the development of tolerance with regular use of this substance. Subtypes of sensitive and non-sensitive PD patients could also explain why some of these patients are able to tolerate high doses of caffeine. |
format | Online Article Text |
id | pubmed-6882139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-68821392019-12-09 Panic Disorder and Chronic Caffeine Use: A Case-control Study Santos, Veruska Andrea Hoirisch-Clapauch, Silvia Nardi, Antonio E. Freire, Rafael Christophe Clin Pract Epidemiol Ment Health Clinical Practice Epidemiology in Mental Health BACKGROUND: Acute administration of caffeine produces panic attacks in most Panic Disorder (PD) patients, but little is known about chronic caffeine use in these patients. OBJECTIVE: To assess caffeine use in patients with PD and to ascertain if caffeine consumption is associated with sociodemographic or clinical features. METHODS: 65 adults with PD and 66 healthy controls were included in the current study. Their caffeine intake within the previous week was quantified with a questionnaire and compared. Harmful caffeine use was defined as consumption above 400 mg/day of caffeine. We tested for correlations between caffeine intake, demographic and clinical features. RESULTS: Patients consumed significantly more caffeine than controls (P < 0.001). 14% (N = 9) of the PD patients made harmful use of caffeine. The use of caffeine-containing medications was observed in 40% (N = 26) of the PD patients and 6% (N = 4) of controls. Consumption of energy drinks was observed in 11% (N = 7) of PD patients and in none of the healthy subjects. Patients reported sleeping significantly less than controls (P < 0.001). In PD patients, caffeine consumption was not correlated with the presence of panic attacks or comorbidity with depression. The use of benzodiazepines or sedative medications was not correlated with caffeine intake. CONCLUSION: High caffeine consumption in PD patients could be explained by the development of tolerance with regular use of this substance. Subtypes of sensitive and non-sensitive PD patients could also explain why some of these patients are able to tolerate high doses of caffeine. Bentham Science Publishers 2019-09-30 /pmc/articles/PMC6882139/ /pubmed/31819760 http://dx.doi.org/10.2174/1745017901915010120 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Clinical Practice Epidemiology in Mental Health Santos, Veruska Andrea Hoirisch-Clapauch, Silvia Nardi, Antonio E. Freire, Rafael Christophe Panic Disorder and Chronic Caffeine Use: A Case-control Study |
title | Panic Disorder and Chronic Caffeine Use: A Case-control Study |
title_full | Panic Disorder and Chronic Caffeine Use: A Case-control Study |
title_fullStr | Panic Disorder and Chronic Caffeine Use: A Case-control Study |
title_full_unstemmed | Panic Disorder and Chronic Caffeine Use: A Case-control Study |
title_short | Panic Disorder and Chronic Caffeine Use: A Case-control Study |
title_sort | panic disorder and chronic caffeine use: a case-control study |
topic | Clinical Practice Epidemiology in Mental Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882139/ https://www.ncbi.nlm.nih.gov/pubmed/31819760 http://dx.doi.org/10.2174/1745017901915010120 |
work_keys_str_mv | AT santosveruskaandrea panicdisorderandchroniccaffeineuseacasecontrolstudy AT hoirischclapauchsilvia panicdisorderandchroniccaffeineuseacasecontrolstudy AT nardiantonioe panicdisorderandchroniccaffeineuseacasecontrolstudy AT freirerafaelchristophe panicdisorderandchroniccaffeineuseacasecontrolstudy |